89bio, Inc.
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
ETNB | NDAQ
Overview
Corporate Details
- ISIN(s):
- US2825591033
- LEI:
- Country:
- United States of America
- Address:
- 655 MONTGOMERY STREET, 94111 SAN FRANCISCO
- Website:
- https://www.89bio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
89bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for liver and cardiometabolic diseases. The company's lead product candidate is pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). Pegozafermin is in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and severe hypertriglyceridemia (SHTG).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all 89bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for 89bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for 89bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
